Genfit S.A. announced the publication of new data on the clinical performance of NIS2+? in older patients, for the detection of at-risk nonalcoholic steatohepatitis (NASH) in Hepatology Communications. In conjunction with Labcorp, a global leader of innovative and comprehensive laboratory services, data reported in the manuscript is the first to show and compare the clinical performance of NIS4® and its recently developed and improved upgrade NIS2+?

in a population of older adults (=65 years of age) with well-established biomarker panels: FIB-4, NFS, ELF and ALT. While previously published data showed that NIS2+? had a high overall clinical performance for the detection of at-risk NASH achieving an AUROC2 of 0.81 in a large study population, the Centers for Medicare & Medicaid Services (CMS) in the US requires peer-reviewed, published data showing that tests, that will be used for patient management, have high assay performance in patients who are =65 years of age.

Results of this study showed the clinical performance of NIS2+? was superior to other tests for the diagnosis of at-risk NASH in patients =65 years of age, greatly assisting with CMS reimbursement efforts. These data support the clinical value of this blood-based test for the diagnosis of at-risk NASH in older adults who would benefit from intensive lifestyle or therapeutic interventions.